everolimus
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
De Novo Renal Transplantation
Conditions
De Novo Renal Transplantation
Trial Timeline
Sep 1, 2006 → —
NCT ID
NCT00464399About everolimus
everolimus is a phase 3 stage product being developed by Novartis for De Novo Renal Transplantation. The current trial status is completed. This product is registered under clinical trial identifier NCT00464399. Target conditions include De Novo Renal Transplantation.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00655252 | Pre-clinical | Completed |
| NCT05108740 | Pre-clinical | Completed |
| NCT05252585 | Approved | Active |
| NCT03525834 | Approved | Completed |
| NCT02962414 | Phase 3 | Active |
| NCT02842749 | Approved | Completed |
| NCT02429869 | Approved | Completed |
| NCT02539459 | Phase 2 | Terminated |
| NCT02687958 | Phase 2 | UNKNOWN |
| NCT02376985 | Phase 3 | Completed |
| NCT02338609 | Approved | Completed |
| NCT02236572 | Phase 2 | Terminated |
| NCT02273752 | Phase 2 | Terminated |
| NCT02201212 | Phase 2 | Completed |
| NCT01864070 | Phase 1 | Withdrawn |
| NCT01997255 | Phase 2 | Withdrawn |
| NCT02096107 | Approved | Completed |
| NCT02017860 | Phase 2 | Completed |
| NCT01636466 | Phase 3 | Terminated |
| NCT01609673 | Pre-clinical | Terminated |
Competing Products
19 competing products in De Novo Renal Transplantation